COVID-19 Update | August 14, 2020
August 14, 2020
The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of August 14, 2020. Notable advancements include:
- Gilead Sciences reached a milestone in its COVID-19 treatment remdesivir by applying for FDA approval.
- Eli Lilly and Regeneron Pharmaceuticals are developing and testing an antibody drug to aid in the fight against COVID-19.
- The University of California, San Francisco, reported they’ve formulated a nasal spray that can help ward off COVID-19.
- Here’s what we know about Bay Area’s 1st coronavirus vaccine trial
ABC 7 News – August 13, 2020
Phase 3 trials of AstraZeneca’s vaccine, developed by Oxford University, will begin in the Bay Area this month, in partnership with UCSF.
- Large study suggests convalescent plasma can help treat COVID-19
STAT – August 13, 2020
The study, which enrolled more than 35,000 patients, found that quickly administering so-called convalescent plasma had a marked effect on mortality for patients with severe cases of COVID-19.
- UCSF researchers develop nasal spray to fight coronavirus. It could be sold in stores
Sacramento Bee – August 13, 2020
Researchers at the University of California, San Francisco, reported Tuesday they have formulated a nasal spray that can help ward off COVID-19.
- Bay Area joins two major coronavirus vaccine trials
San Francisco Chronicle – August 12, 2020
Bay Area residents this week join the global race for a COVID-19 vaccine, with developers of two of the most promising candidates seeking hundreds of volunteers in San Francisco, Oakland and Santa Clara County.
- UCD, Kaiser seeking hundreds in Sacramento, other cities for coronavirus vaccine trial
Sacramento Bee – August 12, 2020
UC Davis Health and Kaiser Permanente will be identifying hundreds of patients in Sacramento and other communities to participate in a clinical trial for a COVID-19 vaccine candidate developed by Pfizer and BioNTech.
- Moderna Signs COVID-19 Vaccine Supply Deal with U.S.
Biospace – August 12, 2020
As one of the leaders in developing a COVID-19 vaccine, Moderna signed a contract with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.
- Companies test antibody drugs to treat, prevent COVID-19
San Diego Union Tribune – August 11, 2020
Companies like Eli Lilly and Regeneron Pharmaceuticals are developing and testing an antibody drug to aid in the fight against COVID-19.
- J&J eyes one billion doses of potential COVID-19 shot in 2021, weighs challenge trials
Reuters – August 11, 2020
Johnson & Johnson could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider challenge trials, a company executive said.
- Gilead seeks FDA approval for COVID-19 drug remdesivir
CBS News – August 10, 2020
Gilead Sciences on Monday applied for approval from the U.S. Food and Drug Administration for its COVID-19 treatment, remdesivir.
- Coronavirus patient at UCSF gets two-drug combo in global experiment
San Francisco Chronicle – August 10, 2020
Doctors at UCSF conducted the study, which is sponsored by the National Institutes of Health, treated their first patient last week with a combination of remdesivir, an antiviral drug, and interferon, an anti-inflammatory used for people with multiple sclerosis.
- Bay Area Biotech Company Develops Promising New Class Of Drug To Treat COVID-19 Patients
CBS Bay Area – August 10, 2020
A Bay Area biotechnology company (Gigagen) has discovered a new way to make a COVID-19 treatment by producing an entirely new class of drugs and soon, the invention will be tested in human clinical trials.
Rely on California Biotechnology Foundation to monitor breaking news and provide updates on the latest advancements in COVID-19 diagnostics, vaccines and treatments.
Stay informed on the latest news and trends on the economic and health benefits of this industry by visiting the new CABiotech.org
If you have any questions about informational briefings contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or email@example.com.